["{\n\"step_by_step_thinking\": \"The question is about teplizumab's promise for diabetes prevention. Teplizumab is an immunologically specific treatment mentioned in the first document as a possibility for spontaneous autoimmune disease. The results of animal studies are encouraging, which suggests that it may have potential in preventing or treating autoimmune diseases like IDDM. The second and third documents discuss the current understanding of IDDM pathogenesis, prediction, and prevention, but they do not specifically mention teplizumab. However, the fourth document discusses the genetic, immunologic, and metabolic components of IDDM, which are relevant to teplizumab's mechanism of action. Overall, based on the available information, it can be concluded that teplizumab may hold promise for diabetes prevention.\",\n\"answer_choice\": \"A\""]